Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

Aron Goldhirsch, John H. Glick, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, H. J. Senn, Kathy S. Albain, Jonas Bergh, Monica Castiglione-Gertsch, Alberto Costa, Jack Cuzick, Nancy Davidson, John F. Forbes, Paul Goss, Jay Harris, Anthony Howell, James N. Ingle, Raimund Jakesz, Jacek Jassem, Manfred KaufmannMiguel Martin, Louis Mauriac, Monica Morrow, Henning T. Mouridsen, Moise Namer, Martine J. Piccart-Gebhart, Kurt Possinger, Kathleen Pritchard, Emiel J T Rutgers, Giuseppe Viale, Arne Wallgren, William C. Wood

Research output: Contribution to journalArticle

879 Citations (Scopus)

Abstract

The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.

Original languageEnglish (US)
Pages (from-to)1569-1583
Number of pages15
JournalAnnals of Oncology
Volume16
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Breast Neoplasms
erbB-2 Genes
Drug Therapy
Therapeutics
Lymph Nodes
Endocrine System Diseases
Switzerland
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., Senn, H. J., ... Wood, W. C. (2005). Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology, 16(10), 1569-1583. https://doi.org/10.1093/annonc/mdi326

Meeting Highlights : International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. / Goldhirsch, Aron; Glick, John H.; Gelber, Richard D.; Coates, Alan S.; Thürlimann, Beat; Senn, H. J.; Albain, Kathy S.; Bergh, Jonas; Castiglione-Gertsch, Monica; Costa, Alberto; Cuzick, Jack; Davidson, Nancy; Forbes, John F.; Goss, Paul; Harris, Jay; Howell, Anthony; Ingle, James N.; Jakesz, Raimund; Jassem, Jacek; Kaufmann, Manfred; Martin, Miguel; Mauriac, Louis; Morrow, Monica; Mouridsen, Henning T.; Namer, Moise; Piccart-Gebhart, Martine J.; Possinger, Kurt; Pritchard, Kathleen; Rutgers, Emiel J T; Viale, Giuseppe; Wallgren, Arne; Wood, William C.

In: Annals of Oncology, Vol. 16, No. 10, 10.2005, p. 1569-1583.

Research output: Contribution to journalArticle

Goldhirsch, A, Glick, JH, Gelber, RD, Coates, AS, Thürlimann, B, Senn, HJ, Albain, KS, Bergh, J, Castiglione-Gertsch, M, Costa, A, Cuzick, J, Davidson, N, Forbes, JF, Goss, P, Harris, J, Howell, A, Ingle, JN, Jakesz, R, Jassem, J, Kaufmann, M, Martin, M, Mauriac, L, Morrow, M, Mouridsen, HT, Namer, M, Piccart-Gebhart, MJ, Possinger, K, Pritchard, K, Rutgers, EJT, Viale, G, Wallgren, A & Wood, WC 2005, 'Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005', Annals of Oncology, vol. 16, no. 10, pp. 1569-1583. https://doi.org/10.1093/annonc/mdi326
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology. 2005 Oct;16(10):1569-1583. https://doi.org/10.1093/annonc/mdi326
Goldhirsch, Aron ; Glick, John H. ; Gelber, Richard D. ; Coates, Alan S. ; Thürlimann, Beat ; Senn, H. J. ; Albain, Kathy S. ; Bergh, Jonas ; Castiglione-Gertsch, Monica ; Costa, Alberto ; Cuzick, Jack ; Davidson, Nancy ; Forbes, John F. ; Goss, Paul ; Harris, Jay ; Howell, Anthony ; Ingle, James N. ; Jakesz, Raimund ; Jassem, Jacek ; Kaufmann, Manfred ; Martin, Miguel ; Mauriac, Louis ; Morrow, Monica ; Mouridsen, Henning T. ; Namer, Moise ; Piccart-Gebhart, Martine J. ; Possinger, Kurt ; Pritchard, Kathleen ; Rutgers, Emiel J T ; Viale, Giuseppe ; Wallgren, Arne ; Wood, William C. / Meeting Highlights : International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. In: Annals of Oncology. 2005 ; Vol. 16, No. 10. pp. 1569-1583.
@article{ab7e573d73114fbdab78ea2aeb58a444,
title = "Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005",
abstract = "The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.",
author = "Aron Goldhirsch and Glick, {John H.} and Gelber, {Richard D.} and Coates, {Alan S.} and Beat Th{\"u}rlimann and Senn, {H. J.} and Albain, {Kathy S.} and Jonas Bergh and Monica Castiglione-Gertsch and Alberto Costa and Jack Cuzick and Nancy Davidson and Forbes, {John F.} and Paul Goss and Jay Harris and Anthony Howell and Ingle, {James N.} and Raimund Jakesz and Jacek Jassem and Manfred Kaufmann and Miguel Martin and Louis Mauriac and Monica Morrow and Mouridsen, {Henning T.} and Moise Namer and Piccart-Gebhart, {Martine J.} and Kurt Possinger and Kathleen Pritchard and Rutgers, {Emiel J T} and Giuseppe Viale and Arne Wallgren and Wood, {William C.}",
year = "2005",
month = "10",
doi = "10.1093/annonc/mdi326",
language = "English (US)",
volume = "16",
pages = "1569--1583",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Meeting Highlights

T2 - International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

AU - Goldhirsch, Aron

AU - Glick, John H.

AU - Gelber, Richard D.

AU - Coates, Alan S.

AU - Thürlimann, Beat

AU - Senn, H. J.

AU - Albain, Kathy S.

AU - Bergh, Jonas

AU - Castiglione-Gertsch, Monica

AU - Costa, Alberto

AU - Cuzick, Jack

AU - Davidson, Nancy

AU - Forbes, John F.

AU - Goss, Paul

AU - Harris, Jay

AU - Howell, Anthony

AU - Ingle, James N.

AU - Jakesz, Raimund

AU - Jassem, Jacek

AU - Kaufmann, Manfred

AU - Martin, Miguel

AU - Mauriac, Louis

AU - Morrow, Monica

AU - Mouridsen, Henning T.

AU - Namer, Moise

AU - Piccart-Gebhart, Martine J.

AU - Possinger, Kurt

AU - Pritchard, Kathleen

AU - Rutgers, Emiel J T

AU - Viale, Giuseppe

AU - Wallgren, Arne

AU - Wood, William C.

PY - 2005/10

Y1 - 2005/10

N2 - The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.

AB - The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.

UR - http://www.scopus.com/inward/record.url?scp=27244436804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27244436804&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi326

DO - 10.1093/annonc/mdi326

M3 - Article

C2 - 16148022

AN - SCOPUS:27244436804

VL - 16

SP - 1569

EP - 1583

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -